title: [Effectiveness of Varenicline with counseling programs on smoking cessation in a targeted clinical setting in China].
abstract: OBJECTIVE
  To evaluate the effectiveness of Varenicline for smoking cessation in a community-based smoking-cessation-clinic (SCC) in Chinese smokers.
  
  
  METHODS
  A prospective observational study was conducted in Beijing, China. 799 smokers (762 men and 37 women) were assessed on data gathered from structured questionnaires at baseline and follow up programs at 1, 3 and 6 months. Trained physician counselors provided free individual counseling and follow-up interviews with brief counseling for all the subjects. 272 subjects were additionally prescribed Varenicline according to their own choice and reported data were compared to those without Varenicline. Outcomes were self-reported, regarding the 7-day point prevalence on abstinence rate and continuous abstinence rates at 1, 3 and 6 month follow-up periods.
  
  
  RESULTS
  At 6-month and by intention-to-treat, the 7-day point prevalence on abstinence rate with Varenicline and counseling, was significantly higher than the group with counseling only (34.6% versus 23.1%; OR = 1.75, 95% CI: 1.27-2.42;P < 0.001). The 3-month continuous abstinence rate at 6 month was higher in the group with Varenicline(31.3% versus 18.2% ;OR = 2.04, 95% CI:1.46-2.86;P < 0.001). Varenicline also showed better outcomes at 1 and 3 month follow-up.
  
  
  CONCLUSIONS
  Varenicline prescription in the smoking cessation clinic appeared to be effective that doubled the rates of quitting among Chinese smokers in the practice at a community-based SCC.
authors.affiliation: Department of Traditional Chinese Medicine and Acupuncture.
authors.forename: Bin
authors.initials: B
authors.lastname: Jiang
authors.affiliation: Department of Epidemiology, Institute of Geriatrics, Beijing Key Laboratory of Aging and Geriatrics. Email: yhe301@x263.net.
authors.forename: Yao
authors.initials: Y
authors.lastname: He
authors.affiliation: Department of Traditional Chinese Medicine and Acupuncture.
authors.forename: Fang
authors.initials: F
authors.lastname: Zuo
authors.affiliation: Department of Epidemiology, Institute of Geriatrics, Beijing Key Laboratory of Aging and Geriatrics.
authors.forename: Lei
authors.initials: L
authors.lastname: Wu
authors.affiliation: Department of Respiration.
authors.forename: Qinghui
authors.initials: Q
authors.lastname: Liu
authors.affiliation: Department of Rehabilitation, Nanlou Faculty of Clinical Medicine, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Respiration.
authors.forename: Changxi
authors.initials: C
authors.lastname: Zhou
authors.affiliation: Public Health, Epidemiology and Biostatistics, University of Birmingham, UK.
authors.forename: Kk
authors.initials: K
authors.lastname: Cheng
authors.affiliation: School of Nursing.
authors.forename: Sc
authors.initials: S
authors.lastname: Chan
authors.affiliation: School of Public Health, The University of Hong Kong, China.
authors.forename: Th
authors.initials: T
authors.lastname: Lam
mesh_terms: D001552:Benzazepines / Q000627:therapeutic use*; D002681:China; D003376:Counseling; D005260:Female; D006801:Humans; D008297:Male; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D011446:Prospective Studies; D011810:Quinoxalines / Q000627:therapeutic use*; D016540:Smoking Cessation; D014029:Tobacco Use Disorder / Q000628:therapy*; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D000068580:Varenicline